Alirocumab May Cause Scleritis With Uveal Effusion

The LDL-cholesterol-lowering agent alirocumab may cause scleritis with uveal effusion, according to the authors of a case report in Annals of Internal Medicine, as reported by Reuters.

“Monoclonal antibody therapy is a relatively new and promising type of treatment that has helped countless people with a variety of conditions, including high cholesterol. Our case of scleritis and uveal effusion following alirocumab serves as a reminder that there may be side effects, or even paradoxical reactions, with these new treatments,” Dr. Royce W. S. Chen of Columbia University Irving Medical Center and NewYork-Presbyterian Hospital in New York City told Reuters Health by email.

Read the full article.